Robert Langer Acquires 93,944 Shares of PureTech Health (LON:PRTC) Stock

PureTech Health plc (LON:PRTC) insider Robert Langer bought 93,944 shares of PureTech Health stock in a transaction dated Wednesday, July 29th. The stock was purchased at an average cost of GBX 1 per share, for a total transaction of £939.44.

PureTech Health Trading Down 0.4%

Shares of PureTech Health stock traded down GBX 0.48 on Friday, hitting GBX 119.12. 512,639 shares of the company traded hands, compared to its average volume of 1,072,302. The company has a current ratio of 6.59, a quick ratio of 2.51 and a debt-to-equity ratio of 6.33. The stock’s 50 day moving average price is GBX 127.71 and its 200-day moving average price is GBX 126.71. The company has a market cap of £289.96 million, a PE ratio of -2.59 and a beta of 0.79. PureTech Health plc has a 52 week low of GBX 104.71 and a 52 week high of GBX 146.40.

Analysts Set New Price Targets

Separately, Peel Hunt restated a “buy” rating and set a GBX 508 price target on shares of PureTech Health in a research note on Monday, July 13th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of GBX 508.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.